Loading...
XJPX
4519
Market cap72bUSD
Aug 03, Last price  
6,687.00JPY
1D
-3.53%
1Q
-18.90%
Jan 2017
497.95%
Name

Chugai Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XJPX:4519 chart
P/E
25.36
P/S
8.75
EPS
263.71
Div yield, %
3.92%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
9.84%
Revenues
1.26t
+7.46%
326,109,000,000344,808,000,000326,937,000,000428,947,000,000379,509,000,000373,516,000,000386,552,000,000423,652,000,000461,109,000,000498,839,000,000491,780,000,000534,199,000,000579,787,000,000686,184,000,000786,945,000,000999,758,000,0001,259,946,000,0001,111,367,000,0001,170,611,000,0001,257,941,000,000
Net income
434.01b
+12.06%
38,417,000,00040,060,000,00039,265,000,00056,634,000,00041,433,000,00035,234,000,00048,205,000,00050,895,000,00050,980,000,00061,125,000,00053,592,000,00072,713,000,00092,488,000,000157,560,000,000214,733,000,000302,995,000,000374,429,000,000325,472,000,000387,317,000,000434,012,000,000
CFO
389.45b
-12.99%
40,538,000,00060,364,000,00039,277,000,00066,461,000,00015,572,000,00069,593,000,00077,299,000,00053,521,000,00037,034,000,00062,918,000,00038,787,000,000107,623,000,000119,074,000,000206,641,000,000205,035,000,000279,626,000,000244,112,000,000409,925,000,000447,600,000,000389,451,000,000
Dividend
Dec 29, 202666 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.
URL
https://www.chugai-pharm.co.jp/
IPO date
Mar 03, 1956
Employees
7,771
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT